SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion A/S announced phase 2 trial data showing its AI-designed…

Evaxion A/S · 6-K filed Apr 17, 2026 at 15:30 ET

At the news

BULLISHIMPACT 8/10

6-K filed Apr 17, 2026 at 15:30 ET

Evaxion A/S announced phase 2 trial data showing its AI-designed personalized cancer vaccine EVX-01 achieved an 86% success rate in triggering tumor-specific immune responses, a key validation of its AI-Immunology platform. The results, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the vaccine's therapeutic potential in advanced melanoma.

  • 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, described as a record high
  • Durable vaccine-specific immune responses observed over two years
  • High de novo T-cell response rate (86%) indicates strong immune system activation
  • Positive correlation between AI-prediction scores and immune response magnitude confirmed

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access